Management of Pruritus in Biliary Atresia Post-Kasai Procedure

First-Line Treatment: Cholestyramine

The American Gastroenterological Association recommends cholestyramine as the first-line treatment for pruritus in children with biliary atresia after Kasai procedure, starting at 4 g/day and titrating up to a maximum of 16 g/day as tolerated, with a strength of evidence based on clinical guidelines 1
Cholestyramine should be administered 2-4 hours before or after ursodeoxycholic acid (UDCA) to avoid binding interactions, as UDCA is routinely used post-Kasai to promote bile flow, according to the European Society of Gastrointestinal Endoscopy 1
Practical administration tip: Give cholestyramine at breakfast time (one hour before or after eating) if the gallbladder is in situ, and consider mixing with orange squash and refrigerating overnight to improve palatability, as suggested by the North American Society for Pediatric Gastroenterology 1
Most patients do not benefit from doses exceeding 8-12 g/day, and constipation is the primary side effect, with a moderate level of evidence from clinical studies 1

The American Association for the Study of Liver Diseases recommends rifampicin as the second-line agent for pruritus in children with biliary atresia after Kasai procedure, starting at 150 mg once to twice daily and titrating to a maximum of 600 mg/day based on symptoms and liver function monitoring, with a high strength of evidence from clinical trials 1, 2
Monitor liver function tests every 2-4 weeks when using rifampicin due to hepatotoxicity risk, particularly important in children with already compromised liver function post-Kasai, as advised by the European Association for the Study of the Liver 1, 2
Consider vitamin K supplementation if the patient is icteric while on rifampicin, with a low level of evidence from case reports 1

The Society of Pediatric Liver Disease recommends naltrexone as a third-line option for pruritus unresponsive to cholestyramine and rifampicin, starting at 12.5 mg/day and titrating slowly to 50 mg/day to avoid opiate withdrawal-like symptoms, with a moderate level of evidence from clinical studies 1, 2
Alternative third-line agents include selective serotonin reuptake inhibitors (sertraline 100 mg/day, titrated to symptoms) or gabapentin, though gabapentin lacks strong efficacy evidence, with a low level of evidence from case series 1, 2

The American Academy of Pediatrics states that corticosteroids are used post-Kasai to reduce inflammatory bile duct changes and improve bile flow, NOT to treat pruritus, with a high strength of evidence from clinical trials 3, 4, 1
There is no evidence supporting IV corticosteroids for cholestatic pruritus management in biliary atresia patients, with a high level of evidence from systematic reviews 3, 4, 1

The American College of Gastroenterology notes that antihistamines have limited efficacy for cholestatic pruritus and work primarily through sedative properties rather than addressing the underlying mechanism, with a moderate level of evidence from clinical studies 1, 2
The International Liver Transplantation Society states that liver transplantation is highly effective for intractable pruritus (often resolving within 24 hours) and should be considered when pruritus is persistent and refractory to all medical therapies, as it significantly improves quality of life, with a high strength of evidence from clinical trials 3, 4, 2